Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
Clover Biopharmaceuticals | Science | Trimer-Tag™
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China | Business Wire
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August | Fierce Biotech
Clover Biopharma nabs $250M-plus for COVID-19 vaccine in expanded CEPI deal | Fierce Biotech
CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian Subsidiary - Clover Biopharmaceuticals
CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI
Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients | Business Wire
Clover and Dynavax initiate dosing in Covid-19 vaccine candidate trial
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate – CEPI
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial
CEPI expands Covid-19 vaccine alliance with Clover Biopharmaceuticals - Pharmaceutical Technology
Clover Biopharmaceuticals | Science | Trimer-Tag™
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
Clover Biopharmaceuticals | Home
GSK recruits Clover Biopharmaceuticals in latest coronavirus effort - PharmaTimes
PharmaBoardroom - China's Clover Biopharmaceuticals Partners with GSK on COVID-19 Vaccine
Clover | Science | Trimer-Tag™ Oncology
Clover Biopharmaceuticals: Phase 1 COVID-19 Vaccine Results - Infectious Disease Advisor
CEPI to provide up to $328m for development of Clover's Covid-19 vaccine
GlaxoSmithKline (GSK) and Clover Biopharmaceuticals
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
